Τίτλος:
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)–adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option. © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Leleu, X.
Beksac, M.
Chou, T.
Dimopoulos, M.
Yoon, S.-S.
Prince, H.M.
Pour, L.
Shelekhova, T.
Chari, A.
Khurana, M.
Zhang, J.
Obreja, M.
Qi, M.
Oriol, A.
Siegel, D.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
albumin; bortezomib; carfilzomib; daratumumab; dexamethasone; hemoglobin; lactate dehydrogenase; lenalidomide; antineoplastic agent; carfilzomib; daratumumab; dexamethasone; monoclonal antibody; oligopeptide, acute kidney failure; aged; Article; cancer survival; clinical outcome; cohort analysis; comparative study; controlled study; drug efficacy; drug safety; drug withdrawal; female; follow up; heart failure; human; hypertension; major clinical study; male; multicenter study; multiple cycle treatment; multiple myeloma; overall response rate; phase 1 clinical trial; phase 3 clinical trial; pneumonia; priority journal; progression free survival; propensity score; randomized controlled trial; respiratory tract infection; sensitivity analysis; septic shock; treatment indication; treatment response time, Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Oligopeptides
DOI:
10.1080/10428194.2020.1832672
